|
| Press Releases |
|
 |
|
| Friday, August 29, 2025 |
|
|
Yunkang Group's 2025 Interim Net Loss Narrows, Demonstrating Strong Operational Resilience |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). more info >> |
|
|
雲康集團2025年中期虧幅縮窄 彰顯強大經營韌性 |
| 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2025年6月30日止（「報告期」）之中期業績。 more info >> |
|
| Monday, March 31, 2025 |
|
|
Yunkang's Revenue Proportion from Joint Construction Business for Medical Institution Alliances and Special Testing Items Continue to Grow in 2024 |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of "in-depth services and lean operations", promoted development with innovation, deepened integrated collaboration among "government, industry, academy, research, medicine, application", accelerated digital application of "AI + medical care", continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience. more info >> |
|
|
雲康集團2024年醫聯體共建業務及特檢項目收益佔比持續增長 |
| 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2024年12月31日止年度（「報告期」）之全年業績。本年度，集團堅定執行「深度服務、精益運營」的總體經營方針，以創新促進發展，深化「政產學研醫用」一體化協同，加快「AI+醫療」數智化應用，持續加強精細化管理，降本增效，展現出強大的經營韌性。 more info >> |
|
| Wednesday, August 28, 2024 |
|
|
Yunkang Group's 2024 Interim Revenue Reaches Approximately RMB380 Million |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2024 (the "Reporting Period"). In the first half of 2024, the Group continued to deeply implement its overall business philosophy of 'in-depth services and lean operations'. more info >> |
|
|
雲康集團2024年中期收益達約人民幣3.80億元 |
| 領先的中國醫學運營服務應供商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2024年6月30日止（「報告期」）之中期業績。2024上半年，集團繼續深入執行「深度服務、精益運營」的總體經營方針，一方面持續深化醫聯體診斷檢測服務模式、快速複製醫檢聯合創新平台，打造創新醫療中心新模式，聚焦「AI+醫療」，在產品創新和模式創新方面成效明顯，推動行業高質發展；另一方面，以快速發展的數字化技術為抓手，堅持降本增效，持續打造精益化運營能力。 more info >> |
|
| Friday, July 5, 2024 |
|
|
Hong Kong Investor Relations Association Announces Winners of the 10th IR Awards 2024 |
| The Hong Kong Investor Relations Association ("HKIRA") today announced the winners of the 10th Investor Relations Awards 2024 (the "IR Awards" or the "Awards"). more info >> |
|
| Friday, March 31, 2023 |
|
|
云康集团公布上市后首份全年业绩 |
| 领先的中国医学运营服务应供商云康集团有限公司（「云康」或「集团」；股份代号：2325）公布截至2022年12月31日止年度（「报告期」）之上巿后首份全年业绩。 more info >> |
|
|
云康集团公佈上市後首份全年業績 |
| 領先的中國醫學運營服務應供商云康集团有限公司（「云康」或「集團」；股份代號：2325）公布截至2022年12月31日止年度（「報告期」）之上巿後首份全年業績。 more info >> |
|
|
Yunkang Group Announces First Annual Results Since Listing |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its first annual results for the year ended December 31, 2022 (the "Reporting Period") since its listing. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 17:29 HKT/SGT
|
|
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎來國際長線接盤 機器人產業生態進入價值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
|
|
|
康哲藥業（867.HK/8A8.SG）：創新藥磷酸蘆可替尼乳膏增加特應性皮炎（AD）適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:31 HKT/SGT
|
|
|
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
Feb 24, 2026 20:19 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
